CTOs on the Move

OptionCare

www.optioncare.com

 
Option Care is a leading provider of home and alternate treatment site infusion services. With a staff of more than 1,700 clinical experts – including specially trained infusion nurses, infusion pharmacists and registered dietitians – Option Care treats patients with a wide range of acute and chronic conditions. Comprehensive therapy management programs are offered for patients with nutrition disorders, bleeding disorders and heart failure, as well as those needing immunoglobulin (IG) therapy and anti-infective therapy. Option Care is able to provide services to 92% of the nation`s population through more than 90 infusion pharmacies and 100 alternate treatment ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.optioncare.com
  • 485 E Half Day Rd Ste 300
    Buffalo Grove, IL USA 60089
  • Phone: 800.879.6137

Executives

Name Title Contact Details

Similar Companies

ABIANT INC

ABIANT INC is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Perimeter Medical Imaging AI

Perimeter Medical Imaging is a medical device company driven to transform cancer surgery with advanced OCT technology for surgeons as they strive for clean margins to avoid re-excisions.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.